You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: CALISTA THERAPEUTICS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. IGF::OT::IGF High-Impact Substance Abuse Prevention Technologies. SBIR Phase I. Period of Performance 7/16/2014-1/15/2015

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIDA

    The overarching objective of this project is to develop an innovative technological tool that will facilitate the implementation of an evidence-based substance abuse prevention program and related health behavior risk programs among military personnel. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Computerized Stage-Matched Intervention for Juvenile Offenders

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): Juvenile crime imposes enormous costs on victims, on society, and on juvenile offenders themselves. However, research assessing the efficacy of interventions for young offenders show, on average, only small effects on recidivism, substance abuse, and other behavioral outcomes. A major problem with existing interventions is that they tend to neglect individual d ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    SBC: EPIVAX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affectingheart and skeletal muscle. Enzyme-replacement therapy with recombinant human (rh)GAA saves the lives of children with Pompe disease. The prognos ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid detection of neonatal sepsis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): The primary goal of this proposed research is to develop a rapid point-of-care (POC) test that can be used to identify neonatal sepsis in high-risk infants in a simple, user-friendly and portable device suitable for usein the NICU setting. Since sepsis presents a very serious threat to neonates, there is an urgent need to obtain confirmation as soon as possible ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. A Smartphone Application for Asthma Patient Self Management and Telemonitoring

    SBC: MJ Datacorp, Ltd.            Topic: NHLBI

    DESCRIPTION (provided by applicant). Several leading authorities, including the World Health Organization (WHO) and the U.S. Department of Health and Human Services (DHHS), have identified asthma as a priority disease area, and have called for action to reduce chronic disability and premature death due to asthma, to enhance HRQOL through education and improved asthma management techniques, and to ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A

    SBC: EPIVAX, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance induction at therapeutic doses for Hemophilia A patients. Hemophiliacs with lt 1% functional FVIII are classified as severe and must receive regular doses of replacement factor. A major issue with su ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government